Compare ALEMBIC PHARMA with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA NOVARTIS ALEMBIC PHARMA/
NOVARTIS
 
P/E (TTM) x 15.6 512.7 3.0% View Chart
P/BV x 3.6 29.7 12.1% View Chart
Dividend Yield % 1.1 1.5 69.1%  

Financials

 ALEMBIC PHARMA   NOVARTIS
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
NOVARTIS
Mar-18
ALEMBIC PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs664758 87.6%   
Low Rs412579 71.2%   
Sales per share (Unadj.) Rs208.7228.4 91.4%  
Earnings per share (Unadj.) Rs31.031.7 97.7%  
Cash flow per share (Unadj.) Rs37.132.8 113.3%  
Dividends per share (Unadj.) Rs5.5010.00 55.0%  
Dividend yield (eoy) %1.01.5 68.3%  
Book value per share (Unadj.) Rs144.2297.1 48.5%  
Shares outstanding (eoy) m188.5224.69 763.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.62.9 88.1%   
Avg P/E ratio x17.421.1 82.4%  
P/CF ratio (eoy) x14.520.4 71.1%  
Price / Book Value ratio x3.72.2 165.9%  
Dividend payout %17.731.5 56.3%   
Avg Mkt Cap Rs m101,46116,505 614.7%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m7,4671,445 516.6%   
Avg. sales/employee Rs ThNM8,441.3-  
Avg. wages/employee Rs ThNM2,163.6-  
Avg. net profit/employee Rs ThNM1,173.1-  
INCOME DATA
Net Sales Rs m39,3475,639 697.8%  
Other income Rs m941,718 5.5%   
Total revenues Rs m39,4417,357 536.1%   
Gross profit Rs m8,736-63 -13,977.3%  
Depreciation Rs m1,15225 4,554.5%   
Interest Rs m18455 332.9%   
Profit before tax Rs m7,4931,575 475.7%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,568792 198.0%   
Profit after tax Rs m5,844784 745.8%  
Gross profit margin %22.2-1.1 -2,003.1%  
Effective tax rate %20.950.3 41.6%   
Net profit margin %14.913.9 106.9%  
BALANCE SHEET DATA
Current assets Rs m19,5779,522 205.6%   
Current liabilities Rs m14,8963,296 451.9%   
Net working cap to sales %11.9110.4 10.8%  
Current ratio x1.32.9 45.5%  
Inventory Days Days9037 245.1%  
Debtors Days Days4528 159.6%  
Net fixed assets Rs m27,09746 58,906.1%   
Share capital Rs m377123 305.5%   
"Free" reserves Rs m26,8117,213 371.7%   
Net worth Rs m27,1887,336 370.6%   
Long term debt Rs m4,9930-   
Total assets Rs m47,77811,105 430.2%  
Interest coverage x41.729.5 141.4%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.5 162.2%   
Return on assets %12.67.6 167.0%  
Return on equity %21.510.7 201.2%  
Return on capital %23.622.2 106.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45361 32,100.2%   
Fx outflow Rs m6,0653,630 167.1%   
Net fx Rs m13,388-3,570 -375.1%   
CASH FLOW
From Operations Rs m8,1201,610 504.4%  
From Investments Rs m-7,556687 -1,099.9%  
From Financial Activity Rs m590-2,677 -22.1%  
Net Cashflow Rs m1,153-380 -303.8%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 2.0 145.0%  
FIIs % 9.1 1.6 568.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 21.5 64.7%  
Shareholders   49,328 41,647 118.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  PLETHICO PHARMA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS